THE US Food and Drug
Administration (FDA) has issued a
Class I recall - the most serious type
of recall reserved only for devices
that may cause serious injury or
death - on Etest® Piperacillin/
Tazobactam 4mg/mL PTC 0.016-256
(PIP/TAZO/CON-4 PTC 256).
Currently used by health care
practitioners in the US to “help
predict if the antibiotic Piperacillin/
Tazobactam (PIP/TAZO) will
be effective in treating serious
infections”, the FDA has since
found that the affected product
“may not actually be effective in
treating those bacteria”, and in
fact could “result in increased time
in the hospital, unnecessary tests
or procedures, treatment failure,
sepsis and even death”.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jan 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.